C-reactive protein and inflammatory cytokines (CRP and cytokines)

C-reactive protein (CRP) is a pentameric acute-phase reactant synthesized by hepatocytes, primarily under the transcriptional control of interleukin-6 (IL-6) [StatPearls: NBK441843]. It functions as a pattern recognition receptor in the innate immune system, binding to phosphocholine on the surface of damaged cells and pathogens to activate the classical complement cascade and facilitate phagocytosis [UniProt: P02741]. The broader category of "inflammatory cytokines" includes signaling proteins like Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-1 (IL-1), which are critical drivers of systemic inflammation and the induction of CRP [PubMed: 27591329]. While CRP is a hallmark biomarker for assessing cardiovascular risk and monitoring inflammatory disease activity, the cytokines themselves are the primary therapeutic targets for biological agents used to treat conditions such as rheumatoid arthritis and inflammatory bowel disease [PubMed: 30204821]. Therapeutic intervention typically involves monoclonal antibodies that neutralize specific cytokines or their receptors to dampen the inflammatory response. This entry is classified as "incorrect" because it aggregates a specific protein biomarker with a diverse functional class of signaling molecules, rather than identifying a single, discrete therapeutic target.

Other names

Acute phase reactantsInflammatory mediatorsSystemic inflammatory markersPro-inflammatory cytokines

The primary mechanism of action for drugs affecting these markers involves the competitive inhibition of pro-inflammatory cytokine receptors or the direct neutralization of circulating cytokines, which subsequently prevents the hepatic induction of C-reactive protein [PubMed: 30204821].